Psoriasis is a lifelong, chronic and immune-mediated skin disease affecting approximately 1-3% of the Caucasian population. Pathogenesis of psoriasis is associated with an increased expression of tumor necrosis factor-alpha (TNF-alpha). TNF-alpha is a pro-inflammatory cytokine and important mediator of cachexia. Anti-TNF-alpha therapies are effective in the treatment of psoriasis. The primary end-point was to investigate retrospectively the effect of anti-TNF-therapies on body weight and body mass index (BMI) in patients with psoriasis under treatment with infliximab, etanercept, adalimumab (anti-TNF-alpha group), efalizumab or methotrexate (control group). The patients were treated for 48 weeks. BMI, weight and disease activity were measured at baseline (week 0), weeks 12, 24 and 48. At week 24 a significant increase in body weight and BMI in the anti-TNF-alpha treatment group compared to the control was observed. BMI and body weight did not interfere with the drugs' efficacy. We report a significant weight-gain associated with three different anti-TNF-alpha therapies in a large number of patients affected with psoriasis.

Saraceno, R., Schipani, C., Mazzotta, A., Esposito, M., DI RENZO, L., DE LORENZO, A., et al. (2008). Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. PHARMACOLOGICAL RESEARCH, 57(4), 290-5 [10.1016/j.phrs.2008.02.006].

Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis

SARACENO, ROSITA;DI RENZO, LAURA;DE LORENZO, ANTONINO;CHIMENTI, SERGIO
2008

Abstract

Psoriasis is a lifelong, chronic and immune-mediated skin disease affecting approximately 1-3% of the Caucasian population. Pathogenesis of psoriasis is associated with an increased expression of tumor necrosis factor-alpha (TNF-alpha). TNF-alpha is a pro-inflammatory cytokine and important mediator of cachexia. Anti-TNF-alpha therapies are effective in the treatment of psoriasis. The primary end-point was to investigate retrospectively the effect of anti-TNF-therapies on body weight and body mass index (BMI) in patients with psoriasis under treatment with infliximab, etanercept, adalimumab (anti-TNF-alpha group), efalizumab or methotrexate (control group). The patients were treated for 48 weeks. BMI, weight and disease activity were measured at baseline (week 0), weeks 12, 24 and 48. At week 24 a significant increase in body weight and BMI in the anti-TNF-alpha treatment group compared to the control was observed. BMI and body weight did not interfere with the drugs' efficacy. We report a significant weight-gain associated with three different anti-TNF-alpha therapies in a large number of patients affected with psoriasis.
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/49 - Scienze Tecniche Dietetiche Applicate
English
Male; Retrospective Studies; Middle Aged; Female; Weight Gain; Methotrexate; Receptors, Tumor Necrosis Factor; Humans; Tumor Necrosis Factor-alpha; Immunoglobulin G; Psoriasis; Body Mass Index; Aged; Adult; Antibodies, Monoclonal
Saraceno, R., Schipani, C., Mazzotta, A., Esposito, M., DI RENZO, L., DE LORENZO, A., et al. (2008). Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. PHARMACOLOGICAL RESEARCH, 57(4), 290-5 [10.1016/j.phrs.2008.02.006].
Saraceno, R; Schipani, C; Mazzotta, A; Esposito, M; DI RENZO, L; DE LORENZO, A; Chimenti, S
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/11049
Citazioni
  • ???jsp.display-item.citation.pmc??? 41
  • Scopus 120
  • ???jsp.display-item.citation.isi??? 112
social impact